Aegerion Pharmaceuticals
Cambridge
About Aegerion Pharmaceuticals
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics/pharmaceuticals to treat cardiovascular and metabolic diseases. It develops lomitapide/AEGR-733, a microsomal triglyceride transfer protein inhibitor small molecule drug for decreasing serum lipids, including cholesterol and triglycerides, as well as to treat atherosclerosis, dyslipidemia, obesity, and pancreatitis. The company also focuses on products for the evaluation and treatment of hyperlipidemia. Aegerion Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Bridgewater, New Jersey.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 101 – 250
- Estimated revenue: $100K – $500K
- Total funding: $63.7M
- Funding stage: M&A
- Last round: Series Unknown (Oct 2010)
- Ticker: nasdaq:AEGR
- Website: aegerion.com
- Phone: (855) 305-2347
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/aegerion-pharmaceuticals-3046038 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.